ACACA and metabolic dysfunction-associated steatotic liver disease: According to our in vitro studies, ACC1 could be a potential clinical marker for patients with NAFLD, as it is detectable at early stages when cellular viability is not yet significantly affected by oxidative stress and cellular permeability, in contrast to AST, which is detected when cellular viability is already compromised.